Key points are not available for this paper at this time.
You have accessJournal of UrologyKidney Cancer: Epidemiology p<0.001), cancer-specific survival (CSS) (HR, 0.99 and 0.92; p<0.001), and overall survival (OS) (HR, 0.99 and 0.95; p<0.001) in multivariable models, respectively. The addition of both IGFBP-2 and -3 to a base multivariable model improved the model's concordance index by 10%, 9%, and 8% for RFS, CSS, and OS, respectively. On DCA adding IGFBP-2 and -3 to these predictive models improved their discriminatory ability to predict RFS, CSS, and OS by a significant margin. CONCLUSIONS: We confirmed that an elevated plasma levels of IGFBP-2 and -3 both are independent and clinically significant predictors of oncologic outcomes and adverse pathological features in UTUC patients treated with RNU. These findings might help guide the clinical decision-making regarding adjuvant systemic therapy and follow-up scheduling. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e842 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mehdi Kardoust Parizi More articles by this author Morgan Rouprêt More articles by this author Jeremy Yuen-Chun Teoh More articles by this author Peter Nyirády More articles by this author Piotr Chlosta More articles by this author Mohammad Abufaraj More articles by this author Vitaly Margulis More articles by this author Marek Babjuk More articles by this author Ekaterina Laukhtina More articles by this author Shahrokh F. Shariat More articles by this author Expand All Advertisement PDF downloadLoading ...
Parizi et al. (Mon,) studied this question.